当前位置: 首页 > 期刊 > 《中国当代医药》 > 20203
编号:13515119
阿帕替尼在恶性肿瘤治疗中的应用研究进展(5)
http://www.100md.com 2020年1月25日 《中国当代医药》 20203
     [24]Syrigos KN,Karapanagiotou E,Boura P,et al.Bevacizumab-induced hypertension:pathogenesis and management[J].Bio Drugs,2011,25(3):159-169.

    [25]Eremina V,Baelde HJ,Quaggin SE.Role of the VEGF-a signaling pathway in the glomerulus:evidence for crosstalk between components of the glomerular filtration barrier[J].Nephron Physiol,2007,106(2):32-37.

    [26]马兴群,成远,陈映霞.VEGF信号通路抑制剂相关蛋白尿的研究进展[J].临床肿瘤学杂志,2015,20(4):357-362.

    [27]Degen A,Alter M,Schenck F,et al.The hand-foot-syndrome associated with medical tumor therapy-classification and management[J].J Dtsch Dermatol Ges,2010,8(9):652-661.

    [28]Belum VR,Wu S,Lacouture ME.Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib:a meta-analysis[J].Invest New Drugs,2013,31(4):1078-1086.

    [29]Li XF,Tan YN,Cao Y,et al.A case report of gastrointestinal hemorrhage and perforation during apatinib treatment of gastric cancer[J].Medicine, 2015,94(39):e1661.

    [30]鄒文,李晓梅,王荣梅.阿帕替尼联合应用替吉奥致严重皮下出血及皮肤破溃1例[J].中国新药与临床杂志,2017, 36(3):176-179.

    (收稿日期:2019-06-03 本文编辑:李二云), http://www.100md.com(左权 向志碧)
上一页1 2 3 4 5